Inhibikase Therapeutics (IKT) Non-cash Items (2021 - 2025)

Inhibikase Therapeutics (IKT) has 4 years of Non-cash Items data on file, last reported at $7.7 million in Q4 2025.

• Non-cash Items for Q4 2025 came in at $7.7 million, down 75.24% year-over-year; the trailing twelve-month figure through Dec 2025 was $7.7 million (down 75.24% YoY), and the FY2025 annual result was $7.7 million, down 75.24% from the prior year.
• Non-cash Items slipped to $7.7 million in Q4 2025 per IKT's latest filing, from $31.1 million in the prior quarter.
• Over five years, Non-cash Items peaked at $31.1 million in Q4 2024 and troughed at $3.4 million in Q4 2021.
• A 4-year average of $11.4 million and a median of $5.6 million in 2022 frame the typical range for Non-cash Items.
• The sharpest annual moves came in 2022 and 2025: Non-cash Items climbed 3.52% in 2022, then sank 75.24% in 2025.
• A 4-year view of Non-cash Items shows it stood at $3.4 million in 2021, then gained by 3.52% to $3.5 million in 2022, then surged by 789.13% to $31.1 million in 2024, then slumped by 75.24% to $7.7 million in 2025.
• Business Quant data shows IKT's Non-cash Items at $7.7 million in Q4 2025, $31.1 million in Q4 2024, and $3.5 million in Q4 2022.